Jul 17, 2023 4:01 pm EDT Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
May 31, 2023 8:00 am EDT Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference
May 15, 2023 4:01 pm EDT Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 02, 2023 8:00 am EDT Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension
May 01, 2023 8:00 am EDT Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
Apr 27, 2023 4:47 pm EDT Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023
Mar 15, 2023 4:01 pm EDT Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 04, 2023 4:30 pm EST Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC
Mar 01, 2023 4:05 pm EST Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
Feb 20, 2023 8:00 am EST Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023
